Pfizer Completes Acquisition of Baxter’s Marketed Vaccines

December 1, 2014 Pfizer Inc. today announced that it has completed the acquisition of Baxter International Inc.’s portfolio of marketed vaccines. The portfolio that was acquired consists of NeisVac-C and FSME-IMMUN/TicoVac. As previously announced, Pfizer also acquired a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured. “NeisVac-C and FSME-IMMUN/Ticovac are a strong fit with our vaccines …

#Vaccine production: #Baxter explore avian #cell-lines, but could algae hold the answer…?

In every industry their is always the endless search to find ‘the-next-BIG-thing', and cell culture vaccine production is no different!  Cell lines from African green monkey to carrots, and Chinese hamster ovary to tobacco have been investigated with varying degrees of success. Now, Baxter have published results on a novel avian cell line, while at the University of Arizona, Dr …